BMS sues Mylan to block Reyataz generic

20-03-2015

Bristol-Myers Squibb (BMS) has sued generic drug maker Mylan for allegedly infringing a patent covering its HIV drug Reyataz (atazanavir sulphate).


Bristol-Myers Squibb, Mylan, Reyataz, ANDA, US District Court for the District of New Jersey

More on this story

BMS and Pfizer reach settlement with Teva
12-09-2017

LSIPR